Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $321.04, down 0.2% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF provides equal-weighted exposure to leading technology firms, tracking the Nasdaq-100 Technology Sector Index. Recent news highlights its role in broad tech exposure, with a 52-week high noted at $248.89 in April 2026, though current levels are significantly higher, indicating strong momentum.

Outlook remains positive given the ETF's focus on high-growth tech sectors, but risks include market volatility and sector concentration. Analyst sentiment is generally supportive, with institutional interest in tech diversification. Investors should weigh the ETF's performance against broader market trends and potential regulatory shifts affecting technology stocks.